[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604760":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":17,"collaborators":11,"id":21,"slug":11,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":24,"acronym":11,"eligibilityCriteria":25,"healthyVolunteers":22,"sex":26,"minAge":27,"maxAge":11,"enrollmentInfo":28,"targetDuration":11,"studyType":31,"phases":11,"briefSummary":32,"conditions":33,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":11},{"fullName":5,"class":6},"Shandong University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"OCS product inspection",null,"Before the operation",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","CROSS_SECTIONAL","Patients with ovarian cancer",{"type":18,"investigatorFullName":19,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Beihua Kong","archiater","100604760",false,"NCT07153705","OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer","Inclusion criteria:\n\n1. Women over 18 years old;\n2. Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;\n3. ECOG \\\u003C 2;\n4. The expected survival period exceeds 6 months;\n5. CA125 ≤ 35 U\u002Fml before initial treatment;\n6. Undergo surgery and adjuvant chemotherapy;\n7. The period between diagnosis and enrollment does not exceed 8 weeks;\n8. Be willing to provide blood samples for OCS testing during the research process;\n9. Sign the informed consent form.\n\nExclusion criteria\n\n1. Have had other malignant tumors within the last five years;\n2. Have received any treatment for ovarian cancer;\n3. Benign ovarian mass;\n4. Non-primary ovarian tumors;\n5. Combined with other malignant tumors;\n6. Patients receiving neoadjuvant therapy;\n7. Pregnancy.","FEMALE","18 Years",{"count":29,"type":30},32,"ESTIMATED","OBSERVATIONAL","To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.",[34],"Ovarian Cancer","NOT_YET_RECRUITING","2025-08-26",{"date":38,"type":39},"2025-09-04","ACTUAL",{"date":41,"type":30},"2025-09-01",{"date":43,"type":30},"2026-04-01",{"name":19,"class":6}]